The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2024 | The deployment of CAR-T therapy for multiple myeloma across Europe
Roberto Mina, MD, University of Turin, Turin, Italy, discusses the deployment of CAR T-cell therapy for patients with multiple myeloma in Europe. Initially, this treatment was approved for patients who were triple-class exposed and had at least three prior lines of therapy. However, CAR T-cell therapy is now being introduced in earlier treatment stages. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iwHRMM 2024), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
